Supernus Pharmaceuticals, Inc. (SUPN) is a Healthcare stock trading at $44.38 (as of 2026-06-18), with a market capitalization of $2.68B and a trailing P/E of -90.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system diseases in the United States. Its products include Trokendi XR and Oxtellar XR for epilepsy and migraine, Qelbree for pediatric ADHD, and several therapies for Parkinson’s disease and related movement disorders.